Matrix Asset Advisors Inc. NY Has $2.70 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Matrix Asset Advisors Inc. NY reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 75.0% in the 4th quarter, HoldingsChannel reports. The firm owned 30,032 shares of the medical equipment provider’s stock after selling 90,174 shares during the quarter. Matrix Asset Advisors Inc. NY’s holdings in Zimmer Biomet were worth $2,700,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rakuten Investment Management Inc. bought a new stake in shares of Zimmer Biomet during the third quarter valued at approximately $37,307,000. Sector Gamma AS lifted its holdings in shares of Zimmer Biomet by 28.0% in the 3rd quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock worth $11,178,000 after purchasing an additional 24,847 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Zimmer Biomet by 29.2% in the 3rd quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock worth $6,019,000 after purchasing an additional 13,812 shares in the last quarter. Border to Coast Pensions Partnership Ltd grew its position in Zimmer Biomet by 6.5% in the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock valued at $35,506,000 after purchasing an additional 22,104 shares during the period. Finally, National Pension Service increased its stake in Zimmer Biomet by 4.5% during the 3rd quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock valued at $38,757,000 after purchasing an additional 16,928 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ZBH. The Goldman Sachs Group downgraded shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective on the stock. in a report on Friday, January 9th. Sanford C. Bernstein boosted their target price on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. Wells Fargo & Company upped their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. Robert W. Baird reaffirmed a “neutral” rating and issued a $100.00 price target (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. Finally, TD Cowen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $106.20.

Zimmer Biomet Trading Up 0.8%

NYSE ZBH opened at $91.13 on Thursday. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. The business has a fifty day simple moving average of $92.18 and a 200 day simple moving average of $93.79. Zimmer Biomet Holdings, Inc. has a 12 month low of $84.59 and a 12 month high of $114.44. The firm has a market capitalization of $17.83 billion, a P/E ratio of 25.74, a PEG ratio of 1.85 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The firm had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 27.12%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.